Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1995 Apr 11;92(8):3278–3282. doi: 10.1073/pnas.92.8.3278

Prolactin-immunoglobulin G complexes from human serum act as costimulatory ligands causing proliferation of malignant B lymphocytes.

A M Walker 1, D W Montgomery 1, S Saraiya 1, T W Ho 1, H S Garewal 1, J Wilson 1, L Lorand 1
PMCID: PMC42149  PMID: 7724552

Abstract

Several lines of evidence indicate that immunoglobulin-bound prolactin found in human serum is not a conventional complex between an anti-prolactin antibody and prolactin but a different type of association of prolactin with the Fab portion of IgG heavy chains. The complex of prolactin with IgG was purified from serum by anti-human prolactin affinity chromatography and was shown to contain close to 1 mole of N epsilon-(gamma-glutamyl)lysine crosslinks per mole of complex, a characteristic feature in structures crosslinked by transglutaminase. Interestingly, the complex caused a proliferation of cells from a subset of patients with chronic lymphocytic leukemia, while it was inactive in a cell proliferation prolactin bioassay. By contrast, human prolactin stimulated the proliferation of cells in the bioassay but had no effect on the complex-responsive cells from the patients. Competition studies with prolactin and free Fc fragment of IgG demonstrated a necessity for engaging both the prolactin and the immunoglobulin receptors for proliferation. More importantly, competition for the growth response by free prolactin and IgG suggests both possible reasons for the slow growth of this neoplasm as well as avenues for control of the disease.

Full text

PDF
3278

Images in this article

3280Fig. 1
on p.3280
3281Fig. 2
on p.3281
3282Fig. 4
on p.3282

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BOYUM A. SEPARATION OF WHITE BLOOD CELLS. Nature. 1964 Nov 21;204:793–794. doi: 10.1038/204793a0. [DOI] [PubMed] [Google Scholar]
  2. Berczi I., Nagy E., Kovacs K., Horvath E. Regulation of humoral immunity in rats by pituitary hormones. Acta Endocrinol (Copenh) 1981 Dec;98(4):506–513. doi: 10.1530/acta.0.0980506. [DOI] [PubMed] [Google Scholar]
  3. Bernton E. W., Meltzer M. S., Holaday J. W. Suppression of macrophage activation and T-lymphocyte function in hypoprolactinemic mice. Science. 1988 Jan 22;239(4838):401–404. doi: 10.1126/science.3122324. [DOI] [PubMed] [Google Scholar]
  4. Carrier M., Russell D. H., Wild J. C., Emery R. W., Copeland J. G. Prolactin as a marker of rejection in human heart transplantation. J Heart Transplant. 1987 Sep-Oct;6(5):290–292. [PubMed] [Google Scholar]
  5. Eitan S., Schwartz M. A transglutaminase that converts interleukin-2 into a factor cytotoxic to oligodendrocytes. Science. 1993 Jul 2;261(5117):106–108. doi: 10.1126/science.8100369. [DOI] [PubMed] [Google Scholar]
  6. Elberg G., Kelly P. A., Djiane J., Binder L., Gertler A. Mitogenic and binding properties of monoclonal antibodies to the prolactin receptor in Nb2 rat lymphoma cells. Selective enhancement by anti-mouse IgG. J Biol Chem. 1990 Sep 5;265(25):14770–14776. [PubMed] [Google Scholar]
  7. Freedman A. S. Immunobiology of chronic lymphocytic leukemia. Hematol Oncol Clin North Am. 1990 Apr;4(2):405–429. [PubMed] [Google Scholar]
  8. Geisler C. H., Larsen J. K., Hansen N. E., Hansen M. M., Christensen B. E., Lund B., Nielsen H., Plesner T., Thorling K., Andersen E. Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. Blood. 1991 Oct 1;78(7):1795–1802. [PubMed] [Google Scholar]
  9. Gout P. W., Beer C. T., Noble R. L. Prolactin-stimulated growth of cell cultures established from malignant Nb rat lymphomas. Cancer Res. 1980 Jul;40(7):2433–2436. [PubMed] [Google Scholar]
  10. Hiestand P. C., Mekler P., Nordmann R., Grieder A., Permmongkol C. Prolactin as a modulator of lymphocyte responsiveness provides a possible mechanism of action for cyclosporine. Proc Natl Acad Sci U S A. 1986 Apr;83(8):2599–2603. doi: 10.1073/pnas.83.8.2599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hivroz C., Grillot-Courvalin C., Brouet J. C., Seligmann M. Heterogeneity of responsiveness of chronic lymphocytic leukemic B cells to B cell growth factor or interleukin 2. Eur J Immunol. 1986 Aug;16(8):1001–1004. doi: 10.1002/eji.1830160821. [DOI] [PubMed] [Google Scholar]
  12. Lorand L., Conrad S. M. Transglutaminases. Mol Cell Biochem. 1984;58(1-2):9–35. doi: 10.1007/BF00240602. [DOI] [PubMed] [Google Scholar]
  13. Matera L., Cesano A., Muccioli G., Veglia F. Modulatory effect of prolactin on the DNA synthesis rate and NK activity of large granular lymphocytes. Int J Neurosci. 1990 Apr;51(3-4):265–267. doi: 10.3109/00207459008999716. [DOI] [PubMed] [Google Scholar]
  14. Matera L., Muccioli G., Cesano A., Bellussi G., Genazzani E. Prolactin receptors on large granular lymphocytes: dual regulation by cyclosporin A. Brain Behav Immun. 1988 Mar;2(1):1–10. doi: 10.1016/0889-1591(88)90001-3. [DOI] [PubMed] [Google Scholar]
  15. McMurray R., Keisler D., Kanuckel K., Izui S., Walker S. E. Prolactin influences autoimmune disease activity in the female B/W mouse. J Immunol. 1991 Dec 1;147(11):3780–3787. [PubMed] [Google Scholar]
  16. Michel E., Parsons J. A. Histochemical demonstration of prolactin binding sites. J Histochem Cytochem. 1989 Jun;37(6):773–779. doi: 10.1177/37.6.2723398. [DOI] [PubMed] [Google Scholar]
  17. Montgomery D. W., Shen G. K., Ulrich E. D., Steiner L. L., Parrish P. R., Zukoski C. F. Human thymocytes express a prolactin-like messenger ribonucleic acid and synthesize bioactive prolactin-like proteins. Endocrinology. 1992 Dec;131(6):3019–3026. doi: 10.1210/endo.131.6.1446637. [DOI] [PubMed] [Google Scholar]
  18. Morgan A., Eaves J., Mockford J. W., Malkovska V. Impaired mitogen responses of the non-leukaemic B cells from patients with chronic lymphocytic leukaemia. Clin Exp Immunol. 1989 Aug;77(2):239–244. [PMC free article] [PubMed] [Google Scholar]
  19. Murthy S. N., Wilson J., Guy S. L., Lorand L. Intramolecular crosslinking of monomeric fibrinogen by tissue transglutaminase. Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10601–10604. doi: 10.1073/pnas.88.23.10601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Nagy E., Berczi I., Wren G. E., Asa S. L., Kovacs K. Immunomodulation by bromocriptine. Immunopharmacology. 1983 Oct;6(3):231–243. doi: 10.1016/0162-3109(83)90023-1. [DOI] [PubMed] [Google Scholar]
  21. Oetting W. S., Walker A. M. Intracellular processing of prolactin. Endocrinology. 1985 Oct;117(4):1565–1569. doi: 10.1210/endo-117-4-1565. [DOI] [PubMed] [Google Scholar]
  22. Palestine A. G., Muellenberg-Coulombre C. G., Kim M. K., Gelato M. C., Nussenblatt R. B. Bromocriptine and low dose cyclosporine in the treatment of experimental autoimmune uveitis in the rat. J Clin Invest. 1987 Apr;79(4):1078–1081. doi: 10.1172/JCI112921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Pfeffer K., Nerl C., Kabelitz D. B cell maturation in chronic lymphocytic leukemia. II. Clonal heterogeneity in the response to various B cell activators and recombinant cytokines (rIFN-gamma, rIFN-alpha, rIL2). Immunobiology. 1987 Sep;175(3):172–182. [PubMed] [Google Scholar]
  24. Russell D. H., Buckley A. R., Montgomery D. W., Larson N. A., Gout P. W., Beer C. T., Putnam C. W., Zukoski C. F., Kibler R. Prolactin-dependent mitogenesis in Nb 2 node lymphoma cells: effects of immunosuppressive cyclopeptides. J Immunol. 1987 Jan 1;138(1):276–284. [PubMed] [Google Scholar]
  25. Russell D. H., Kibler R., Matrisian L., Larson D. F., Poulos B., Magun B. E. Prolactin receptors on human T and B lymphocytes: antagonism of prolactin binding by cyclosporine. J Immunol. 1985 May;134(5):3027–3031. [PubMed] [Google Scholar]
  26. Schranz V., Gráf F. Prognostic significance of the heterogenous expression of IgG Fc receptors in B-cell chronic lymphocytic leukemia. Ann Hematol. 1992 Mar;64(3):140–145. doi: 10.1007/BF01697401. [DOI] [PubMed] [Google Scholar]
  27. Shen G. K., Montgomery D. W., Ulrich E. D., Mahoney K. R., Zukoski C. F. Up-regulation of prolactin gene expression and feedback modulation of lymphocyte proliferation during acute allograft rejection. Surgery. 1992 Aug;112(2):387–394. [PubMed] [Google Scholar]
  28. Shiu R. P., Elsholtz H. P., Tanaka T., Friesen H. G., Gout P. W., Beer C. T., Noble R. L. Receptor-mediated mitogenic action of prolactin in a rat lymphoma cell line. Endocrinology. 1983 Jul;113(1):159–165. doi: 10.1210/endo-113-1-159. [DOI] [PubMed] [Google Scholar]
  29. Spangelo B. L., Hall N. R., Ross P. C., Goldstein A. L. Stimulation of in vivo antibody production and concanavalin-A-induced mouse spleen cell mitogenesis by prolactin. Immunopharmacology. 1987 Sep;14(1):11–20. doi: 10.1016/0162-3109(87)90004-x. [DOI] [PubMed] [Google Scholar]
  30. Tanaka T., Shiu R. P., Gout P. W., Beer C. T., Noble R. L., Friesen H. G. A new sensitive and specific bioassay for lactogenic hormones: measurement of prolactin and growth hormone in human serum. J Clin Endocrinol Metab. 1980 Nov;51(5):1058–1063. doi: 10.1210/jcem-51-5-1058. [DOI] [PubMed] [Google Scholar]
  31. Viselli S. M., Stanek E. M., Mukherjee P., Hymer W. C., Mastro A. M. Prolactin-induced mitogenesis of lymphocytes from ovariectomized rats. Endocrinology. 1991 Aug;129(2):983–990. doi: 10.1210/endo-129-2-983. [DOI] [PubMed] [Google Scholar]
  32. Walker A. M., Peabody C. A., Ho T. W., Warner M. D. 50 kD prolactin binding protein in schizophrenics on neuroleptic medication. J Psychiatry Neurosci. 1992 Jun;17(2):61–67. [PMC free article] [PubMed] [Google Scholar]
  33. Wang Y. F., Jia H., Walker A. M., Cukierman S. K-current mediation of prolactin-induced proliferation of malignant (Nb2) lymphocytes. J Cell Physiol. 1992 Jul;152(1):185–189. doi: 10.1002/jcp.1041520123. [DOI] [PubMed] [Google Scholar]
  34. Wheeler K., Pound J. D., Gordon J., Jefferis R. Engagement of CD40 lowers the threshold for activation of resting B cells via antigen receptor. Eur J Immunol. 1993 May;23(5):1165–1168. doi: 10.1002/eji.1830230528. [DOI] [PubMed] [Google Scholar]
  35. Whyte A., Williams R. O. Bromocriptine suppresses postpartum exacerbation of collagen-induced arthritis. Arthritis Rheum. 1988 Jul;31(7):927–928. doi: 10.1002/art.1780310717. [DOI] [PubMed] [Google Scholar]
  36. Zaknoen S. L., Christian S. L., Suen R., Van Ness B., Kay N. E. B-chronic lymphocytic leukemia cells contain both endogenous kappa immunoglobulin mRNA and critical immunoglobulin gene activation transcription factors. Leukemia. 1992 Jul;6(7):675–679. [PubMed] [Google Scholar]
  37. van de Winkel J. G., Capel P. J. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today. 1993 May;14(5):215–221. doi: 10.1016/0167-5699(93)90166-I. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES